DAVOS, Switzerland, Jan. 28 /PRNewswire/ -- 23andMe, Inc., an industry leader in personal genetics, and mondoBIOTECH AG, a Swiss research company dedicated to the development of treatments for rare diseases, today announced at the World Economic Forum in Davos, Switzerland, that they are collaborating to advance research of rare diseases. The announcement marks the return of the companies to the World Economic Forum, where they both were recognized as Technology Pioneers in 2008.
23andMe and mondoBIOTECH will work together to facilitate research of the genetic bases of rare and potentially fatal diseases, such as Pulmonary Arterial Hypertension, Sarcoidosis, and Pulmonary Fibrosis, the genetics of which are poorly understood. mondoBIOTECH will identify individuals suffering from certain rare diseases and sponsor their enrollment in the 23andMe Personal Genome Service(TM). Researchers then will be able to study the genetic information collected, along with any phenotypic information provided, in clinical trials, to understand potential causes of these diseases. 23andMe will coordinate genome-wide association studies for mondoBIOTECH affiliates using its research infrastructure and bioinformatics expertise.
The Illumina DNA Analysis technology used by 23andMe is the world's leading technology for genome-wide association studies and has the unique capability to include custom markers. This feature enabled 23andMe to select SNPs (single nucleotide polymorphisms), or variants that provide coverage of genes associated with drug response, information that is proving to be critical for the development of personalized medicine. In addition to having over half a million markers available for disease research, these "pharmacogenetic" indicators included in the 23andMe dataset could provide invalua
|SOURCE 23andMe, Inc.; mondoBIOTECH AG|
Copyright©2009 PR Newswire.
All rights reserved